|
CCNG1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.90280013967481E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.9416996029712E-10 |
| Normal-vs-Stage2 |
1.19190000003044E-06 |
| Normal-vs-Stage3 |
1.22130000002052E-07 |
| Normal-vs-Stage4 |
7.74230000000209E-05 |
| Stage1-vs-Stage2 |
1.747570E-01 |
| Stage1-vs-Stage3 |
9.511200E-01 |
| Stage1-vs-Stage4 |
2.131400E-01 |
| Stage2-vs-Stage3 |
1.675570E-01 |
| Stage2-vs-Stage4 |
4.936000E-02 |
| Stage3-vs-Stage4 |
3.115800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.50349996078603E-10 |
| Normal-vs-AfricanAmerican |
1.64566999999449E-05 |
| Normal-vs-Asian |
5.68009999999397E-05 |
| Caucasian-vs-AfricanAmerican |
7.722200E-01 |
| Caucasian-vs-Asian |
3.303200E-01 |
| AfricanAmerican-vs-Asian |
3.697200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.12839999566461E-08 |
| Normal-vs-Female |
4.75799954990919E-10 |
| Male-vs-Female |
7.382000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66339997331733E-09 |
| Normal-vs-Age(41-60Yrs) |
9.81350001261205E-09 |
| Normal-vs-Age(61-80Yrs) |
7.58829999947253E-08 |
| Normal-vs-Age(81-100Yrs) |
3.873900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.133600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.856800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.413600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.795600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.570800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.725200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.789600E-01 |
| Classical-VS-Follicular |
3.802800E-01 |
| Classical-VS-Other |
5.546000E-01 |
| Classical-VS-Normal |
9.25910459415036E-11 |
| Tall-VS-Follicular |
2.892000E-01 |
| Tall-VS-Other |
7.197800E-01 |
| Tall-VS-Normal |
6.20400000039822E-07 |
| Follicular-VS-Other |
3.075400E-01 |
| Follicular-VS-Normal |
1.76892999999012E-05 |
| Other-VS-Normal |
6.677800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.12779999783541E-08 |
| Normal-vs-N1 |
3.648300E-04 |
| N0-vs-N1 |
6.620000E-01 |
|
|
